EISAI INC Company Profile

✉ Email this page to a colleague

EISAI INC has eleven approved drugs.

There are fifteen US patents protecting EISAI INC drugs.

There are three hundred and twenty-three patent family members on EISAI INC drugs in forty-two countries and thirty-nine supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-002	Apr 7, 2020		RX	Yes	Yes	10,702,529	⤷ Sign Up	Y			⤷ Sign Up
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes	11,090,386*PED	⤷ Sign Up			Y	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-002	Nov 14, 2008	8,076,362*PED	⤷ Sign Up
Eisai Inc	BANZEL	rufinamide	SUSPENSION;ORAL	201367-001	Mar 3, 2011	7,750,028*PED	⤷ Sign Up
Eisai Inc	LUSEDRA	fospropofol disodium	SOLUTION;INTRAVENOUS	022244-001	Dec 12, 2008	6,204,257	⤷ Sign Up
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-001	Nov 14, 2008	8,076,362*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	4 mg and 10 mg	➤ Subscribe	2019-02-13
➤ Subscribe	Tablets	100 mg, 200 mg and 400 mg	➤ Subscribe	2012-11-14
➤ Subscribe	Orally Disintegrating Tablets	5 mg and 10 mg	➤ Subscribe	2010-06-30
➤ Subscribe	Tablets	23 mg	➤ Subscribe	2013-07-09
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2014-06-16

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1415987	132016000024218	Italy	⤷ Sign Up	PRODUCT NAME: LENVATINIB O UN SUO SALE ACCETTABILE FARMACEUTICAMENTE O SUO IDRATO(LENVIMA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1002/001-002, 20150601
1698623	PA2015039	Lithuania	⤷ Sign Up	PRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
1698623	261 5023-2015	Slovakia	⤷ Sign Up	PRODUCT NAME: LENVATINIB MESYLAT; REGISTRATION NO/DATE: EU/1/15/1002/001 - EU/1/15/1002/002 20150601
1087960	1191021-3	Sweden	⤷ Sign Up	PRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT EU/1/11/678/001-002, 2011-03-17 EG
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.